ITEMS IN AFP WITH KEYWORD:
Insulin therapy is recommended for patients with type 2 diabetes mellitus and an initial A1C level greater than 9 percent, or if diabetes is uncontrolled despite optimal oral glycemic therapy. Insulin therapy may be initiated as augmentation, starting at 0.3 unit per kg, or as replacement, starting ...
What are the effects of treatments to prevent progression of nephropathy in persons with type 1 and type 2 diabetes and early and late nephropathy?
Dec 15, 2010 Issue
Updated Recommendations on Daily Aspirin Use in Patients with Diabetes [Practice Guidelines]
To address the uncertainties about aspirin use in persons with diabetes, experts from the American Diabetes Association, American Heart Association, and American College of Cardiology Foundation reviewed the current evidence and updated the 2007 recommendations.
Dec 15, 2010 Issue
Thiazolidinedione Therapy for Managing Metabolic Syndrome [FPIN's Clinical Inquiries]
There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting.
Nov 1, 2010 Issue
Does Metformin Increase the Risk of Fatal or Nonfatal Lactic Acidosis? [Cochrane for Clinicians]
In patients without standard contraindications to metformin therapy, metformin does not increase the risk of lactic acidosis.
The 2010 American Diabetes Association's (ADA) “Standards of Medical Care in Diabetes” includes revisions based on new evidence. Several sections have undergone major changes.
Photo Quiz presents readers with a clinical challenge based on a photograph or other image.
Diabetic peripheral neuropathic pain affects the functionality, mood, and sleep patterns of approximately 10 to 20 percent of patients with diabetes mellitus. Treatment goals include restoring function and improving pain control. Patients can realistically expect a 30 to 50 percent reduction in disc...
Saxagliptin lowers A1C levels to a lesser extent and is much more expensive than first-line therapy with metformin. Its ability to decrease diabetes-related complications, including mortality, is not known. It is a DPP-4 inhibitor that has a more significant drug interaction profile than sitagliptin and offers little cost advantage.